ArticleNigerian medical journal : journal of the Nigeria Medical Association
NGAL Superiority to Creatinine in the Diagnosis of Renal Injury in a Pediatric Tertiary Hospital Setting.
Article in Nigerian medical journal : journal of the Nigeria Medical Association. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute kidney injury (AKI) is related with higher death rates, longer hospital admissions, and an increased chance of developing chronic kidney disease (CKD). Serum creatinine, a conventional biomarker for AKI diagnosis, has limitations since it rises slowly after renal injury and is dependent on muscle mass and hydration state. Neutrophil gelatinase-associated lipocalin (NGAL) has emerged as a promising early biomarker, appearing in urine and plasma within two hours of kidney injury. This study investigates the diagnostic accuracy of NGAL against serum creatinine in diagnosing AKI in pediatric patients. The aim of this study is to assess the sensitivity and specificity of •NGAL in diagnosing AKI in pediatric patients compared to serum creatinine. By assessing the reliability of NGAL, the study aims to enhance early detection and management techniques for AKI in children. Methodology: A cross-sectional analytic study was carried out over a 12-month period at a tertiary hospital's pediatric nephrology department. The study included 200 children aged 1 month to 18 years who had been admitted with symptoms that put them at risk for AKI, such as sepsis, dehydration, and nephrotoxic medication exposure. Blood samples were taken at admission and 24 hours later to determine serum creatinine and NGAL levels. An enzymatic colorimetric technique was used to determine serum creatinine, and an enzyme-linked immunosorbent assay (ELISA) was used to detect NGAL. Data was analyzed with SPSS software, and diagnostic performance was assessed using receiver operating characteristic (ROC) curve analysis. Result: NGAL revealed superior diagnostic accuracy, with an area under the curve (AUC) of 0.94 against 0.72 for creatinine. NGAL demonstrated greater sensitivity (92% vs. 68%) and specificity (88% vs. 62%), especially in infants. The ROC curve demonstrated NGAL's excellent diagnostic performance in all pediatric age groups. Conclusion: This study shows that NGAL is a more reliable early biomarker for AKI in pediatric patients than serum creatinine. Its implementation in clinical practice could lead to early diagnosis and treatments, lowering the risk of severe kidney injury and improving pediatric patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.